This is a compact, public-use question map for sharpening an early healthcare commercial-diligence hypothesis.

The objective is not to create an exhaustive diligence checklist. It is to identify the assumptions most capable of breaking the investment case before the analysis becomes too anchored on the management plan or market-growth narrative.

1. Market

Start by challenging whether the attractive market story is actually relevant to the target.

Questions to ask:

  • Is reported category growth genuinely addressable by the target?

  • Is growth driven by volume, price, mix, penetration or capacity expansion?

  • Is the underlying profit pool growing alongside revenue?

  • Which parts of demand are structurally attractive and which may be temporary?

  • Does the target participate in the fastest-growing parts of the market?

  • Which assumptions depend on regulation, reimbursement or policy remaining favourable?

  • Could new capacity or competitive entry absorb much of the expected growth?

Red flag: A strong market CAGR is doing most of the work in the investment thesis.

2. Customer

Healthcare businesses often involve multiple decision-makers rather than a single customer.

Questions to ask:

  • Who uses the product or service?

  • Who chooses it?

  • Who pays?

  • Who influences the decision?

  • Who can block adoption?

  • How concentrated is revenue by customer, physician, institution or channel?

  • How durable are the most important relationships?

  • Is customer retention structural or merely historical?

  • What evidence shows that customers would follow the business as it expands?

  • How sensitive is demand to pricing, service levels or individual relationships?

Red flag: Historical customer behaviour is assumed to continue even though the business model, geography or commercial proposition is changing.

3. Competition

The relevant question is not simply who the competitors are, but how competitors could respond to the target’s growth plan.

Questions to ask:

  • What would a well-funded competitor do differently?

  • Is differentiation visible to customers or primarily claimed by management?

  • How easily can products, services or commercial practices be replicated?

  • Does the growth plan depend on competitors remaining passive?

  • Are there segments where incumbents have stronger relationships, channels or economics?

  • Could new entrants change pricing or customer-acquisition economics?

  • What protects the target if the market becomes more attractive?

Red flag: The business plan assumes share gain without explaining the mechanism through which share will be taken.

4. Economics

Growth is only valuable if the economics remain attractive as the business scales.

Questions to ask:

  • What happens to margins as the company grows?

  • Which costs are genuinely variable, semi-variable or fixed?

  • Does expansion improve operating density or dilute it?

  • How much upfront investment is required to create future revenue?

  • Do customer-acquisition economics change in newer markets or segments?

  • Are mature-unit economics being applied too easily to new units?

  • What happens to returns if ramp-up takes longer than management expects?

  • Which assumptions drive the greatest sensitivity in EBITDA or cash generation?

Red flag: Scale economics are assumed rather than demonstrated.

5. Replication and scalability

For multi-site, multi-city or multi-segment healthcare businesses, replication deserves explicit attention.

Questions to ask:

  • Which elements of the existing model can genuinely be standardised?

  • Which depend on founder relationships, local clinicians, referral patterns or institutional access?

  • Can new sites achieve comparable utilisation and economics?

  • Are management capabilities deep enough to support expansion?

  • Does geographic growth require a different commercial or operating model?

  • Which elements of success become harder rather than easier at scale?

Red flag: One successful unit, city or customer cohort is treated as proof of platform scalability.

6. Execution

Finally, isolate what management must accomplish for the investment case to work.

Questions to ask:

  • Which assumptions require a capability that does not exist today?

  • Which initiatives have already been demonstrated?

  • Which remain hypotheses?

  • Does the growth plan require simultaneous success across too many initiatives?

  • Which milestones must occur before the next phase of investment?

  • Where does execution depend on recruiting scarce talent, physicians, partners or channels?

  • What is the single hardest assumption in the management plan?

  • What happens to the investment case if that assumption is delayed or fails?

Red flag: The base case requires several unproven initiatives to succeed at the same time.

The synthesis

I find it useful to reduce the diligence back to six questions:

  1. Is the market genuinely attractive for this target?

  2. Are customer relationships and behaviours durable?

  3. Does the target possess a defensible advantage?

  4. Do the economics remain attractive as the business scales?

  5. Can the model be replicated?

  6. Can management actually execute the investment case?

The purpose of the red-flag map is not simply to identify risks.

It is to distinguish risks that can be underwritten or addressed through value creation from assumptions that fundamentally weaken the investment thesis.

A compelling healthcare market story is only the starting point. Commercial diligence has to establish whether the specific company can capture that opportunity, at attractive economics, with an executable path to growth.